Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arnold L Oronsky

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Case Reports in Oncology|November 25, 2015
Dysphonia after Bevacizumab Rechallenge: A Case ReportCorey A Carter, Scott Z Caroen, Arnold L Oronsky, et al.
Medical Oncology (Northwood, London, England)|May 1, 2016
"No patient left behind": an alternative to "the War on Cancer" metaphorBryan T Oronsky, Corey A Carter, Arnold L Oronsky, et al.
Case Reports in Oncology|November 25, 2015
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine TumorCorey A Carter, Aiste Degesys, Bryan Oronsky, et al.
Oncoimmunology|November 11, 2017
No patient left behind: The promise of immune priming with epigenetic agentsCorey A Carter, Bryan T Oronsky, Joseph Roswarski, et al.
Frontiers in Oncology|July 1, 2015
Episensitization: Defying Time's ArrowBryan T Oronsky, Arnold L Oronsky, Michelle Lybeck, et al.
Case Reports in Oncology|April 12, 2016
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum DoubletsCorey A Carter, Bryan T Oronsky, Scott Z Caroen, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Case Reports in Oncology|November 25, 2015
Dysphonia after Bevacizumab Rechallenge: A Case ReportCorey A Carter, Scott Z Caroen, Arnold L Oronsky, et al.
Medical Oncology (Northwood, London, England)|May 1, 2016
"No patient left behind": an alternative to "the War on Cancer" metaphorBryan T Oronsky, Corey A Carter, Arnold L Oronsky, et al.
Case Reports in Oncology|November 25, 2015
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine TumorCorey A Carter, Aiste Degesys, Bryan Oronsky, et al.
Oncoimmunology|November 11, 2017
No patient left behind: The promise of immune priming with epigenetic agentsCorey A Carter, Bryan T Oronsky, Joseph Roswarski, et al.
Frontiers in Oncology|July 1, 2015
Episensitization: Defying Time's ArrowBryan T Oronsky, Arnold L Oronsky, Michelle Lybeck, et al.
Case Reports in Oncology|April 12, 2016
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum DoubletsCorey A Carter, Bryan T Oronsky, Scott Z Caroen, et al.
Pageof 1